132 related articles for article (PubMed ID: 38091970)
1. Efficacy of Cetuximab Combined with Paclitaxel in Patients with Recurrent Salivary Gland Carcinoma: A Retrospective Observational Study.
Sato R; Yuasa R; Kumai T; Wakisaka R; Komatsuda H; Kono M; Yamaki H; Ishida Y; Wada T; Takahara M; Katada A
ORL J Otorhinolaryngol Relat Spec; 2024; 86(1):41-49. PubMed ID: 38091970
[TBL] [Abstract][Full Text] [Related]
2. Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Suzuki S; Toyoma S; Kawasaki Y; Koizumi K; Iikawa N; Shiina K; Endo T; Abe T; Kouga T; Yamada T
Medicina (Kaunas); 2021 Oct; 57(11):. PubMed ID: 34833369
[No Abstract] [Full Text] [Related]
3. Weekly Cetuximab and Paclitaxel for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Fushimi C; Baba D; Masubuchi T; Yamazaki M; Kitani Y; Kitajima T; Tanaka J; Hanyu K; Tanaka N; Miura K; Tada Y
In Vivo; 2020; 34(5):2653-2657. PubMed ID: 32871796
[TBL] [Abstract][Full Text] [Related]
4. Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01).
Kim Y; Lee SJ; Lee JY; Lee SH; Sun JM; Park K; An HJ; Cho JY; Kang EJ; Lee HY; Kim J; Keam B; Kim HR; Lee KE; Choi MY; Lee KH; Ahn MJ
Cancer; 2017 Jun; 123(11):1958-1964. PubMed ID: 28102887
[TBL] [Abstract][Full Text] [Related]
5. Clinical impact of weekly paclitaxel plus cetuximab is comparable to the EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma.
Motai R; Sawabe M; Kadowaki S; Sasaki E; Nishikawa D; Suzuki H; Beppu S; Terada H; Hanai N
Int J Clin Oncol; 2021 Jul; 26(7):1188-1195. PubMed ID: 33821363
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel Plus Cetuximab as 1st Line Chemotherapy in Platinum-Based Chemoradiotherapy-Refractory Patients With Squamous Cell Carcinoma of the Head and Neck.
Enokida T; Okano S; Fujisawa T; Ueda Y; Uozumi S; Tahara M
Front Oncol; 2018; 8():339. PubMed ID: 30211118
[No Abstract] [Full Text] [Related]
7. Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter clinical study.
Wakasaki T; Manako T; Yasumatsu R; Hara H; Toh S; Masuda M; Yamauchi M; Kuratomi Y; Nishimura E; Takeuchi T; Matsuo M; Jiromaru R; Hashimoto K; Komune N; Nakagawa T
PLoS One; 2022; 17(7):e0271907. PubMed ID: 35901098
[TBL] [Abstract][Full Text] [Related]
8. A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy.
Shirakawa T; Kato K; Nagashima K; Nishikawa A; Sawada R; Takahashi N; Shoji H; Sasaki Y; Honma Y; Iwasa S; Takashima A; Okita N; Hamaguchi T; Yamada Y; Shimada Y
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1207-15. PubMed ID: 25267597
[TBL] [Abstract][Full Text] [Related]
9. Multicenter Retrospective Study of Weekly Cetuximab Plus Paclitaxel for Recurrent or Metastatic Oral Squamous Cell Carcinoma.
Naruse T; Yanamoto S; Otsuru M; Yamakawa N; Kirita T; Shintani Y; Matsumura T; Okura M; Sasaki M; Ota Y; Yamada SI; Kurita H; Umeda M;
Anticancer Res; 2021 Nov; 41(11):5785-5791. PubMed ID: 34732452
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study.
Kurzrock R; Bowles DW; Kang H; Meric-Bernstam F; Hainsworth J; Spigel DR; Bose R; Burris H; Sweeney CJ; Beattie MS; Blotner S; Schulze K; Cuchelkar V; Swanton C
Ann Oncol; 2020 Mar; 31(3):412-421. PubMed ID: 32067683
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.
Hitt R; Irigoyen A; Cortes-Funes H; Grau JJ; García-Sáenz JA; Cruz-Hernandez JJ;
Ann Oncol; 2012 Apr; 23(4):1016-22. PubMed ID: 21865152
[TBL] [Abstract][Full Text] [Related]
12. Biweekly administration of cetuximab in Japanese patients with recurrent or metastatic head and neck cancer.
Tanaka N; Enokida T; Fujisawa T; Okano S; Wada A; Sato M; Tanaka H; Takeshita N; Tahara M
Int J Clin Oncol; 2022 Nov; 27(11):1669-1674. PubMed ID: 35943644
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Cetuximab-Based Salvage Chemotherapy After Checkpoint Inhibitors in Head and Neck Cancer.
Cabezas-Camarero S; Cabrera-Martín MN; Merino-Menéndez S; Paz-Cabezas M; García-Barberán V; Sáiz-Pardo Sanz M; Iglesias-Moreno M; Alonso-Ovies A; Pérez-Segura P
Oncologist; 2021 Jun; 26(6):e1018-e1035. PubMed ID: 33751752
[TBL] [Abstract][Full Text] [Related]
14. Combination chemotherapy of carboplatin and paclitaxel for advanced/metastatic salivary gland carcinoma patients: differences in responses by different pathological diagnoses.
Nakano K; Sato Y; Sasaki T; Shimbashi W; Fukushima H; Yonekawa H; Mitani H; Kawabata K; Takahashi S
Acta Otolaryngol; 2016 Sep; 136(9):948-51. PubMed ID: 27094013
[TBL] [Abstract][Full Text] [Related]
15. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
16. A Single-Arm, Prospective, Phase II Study of Cisplatin Plus Weekly Docetaxel as First-Line Therapy in Patients with Metastatic or Recurrent Salivary Gland Cancer.
Kim HR; Lee SJ; Park S; Jung HA; Lee SH; Jeong HS; Chung MK; Ahn MJ
Cancer Res Treat; 2022 Jul; 54(3):719-727. PubMed ID: 34727492
[TBL] [Abstract][Full Text] [Related]
17. Carboplatin and Docetaxel in Patients With Salivary Gland Carcinoma: A Retrospective Study.
Okada T; Saotome T; Nagao T; Masubuchi T; Fushimi C; Matsuki T; Takahashi H; Miura K; Tsukahara K; Tada Y
In Vivo; 2019; 33(3):843-853. PubMed ID: 31028207
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in patients with recurrent high-grade neuroendocrine cervical cancer: a Neuroendocrine Cervical Tumor Registry (NeCTuR) study.
Frumovitz M; Chisholm GB; Jhingran A; Ramalingam P; Flores-Legarreta A; Bhosale P; Gonzales NR; Hillman RT; Salvo G
Am J Obstet Gynecol; 2023 Apr; 228(4):445.e1-445.e8. PubMed ID: 36516952
[TBL] [Abstract][Full Text] [Related]
19. Retrospective Study of Cisplatin/Carboplatin, 5-Fluorouracil Plus Cetuximab (EXTREME) for Advanced-stage Salivary Gland Cancer.
Nakano T; Yasumatsu R; Hashimoto K; Kuga R; Hongo T; Yamamoto H; Matsuo M; Wakasaki T; Jiromaru R; Manako T; Toh S; Masuda M; Yamauchi M; Kuratomi Y; Uryu H; Nakashima T; Tamae A; Tanaka R; Taura M; Takeuchi T; Yoshida T; Nakagawa T
In Vivo; 2022; 36(2):979-984. PubMed ID: 35241559
[TBL] [Abstract][Full Text] [Related]
20. A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer.
Rodriguez CP; Wu QV; Voutsinas J; Fromm JR; Jiang X; Pillarisetty VG; Lee SM; Santana-Davila R; Goulart B; Baik CS; Chow LQM; Eaton K; Martins R
Clin Cancer Res; 2020 Feb; 26(4):837-845. PubMed ID: 31796519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
